Q-omics provides the consensus-scored NXNL2 profile across patient tissues and cancer cell-line models. NXNL2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NXNL2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, NXNL2 RNA expression shows 16,049 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KICH, and THYM as cancer lineages where NXNL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXNL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXNL2 survival associations across molecular data types. NXNL2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXNL2 RNA expression–survival associations across cancer types. High NXNL2 expression shows unfavorable associations in LUAD and PAAD, but favorable associations in UCEC, KIRC, BRCA and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NXNL2 RNA expression.
This table summarizes NXNL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NXNL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXNL2 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRC, HNSC, THCA and CHOL. The KICH box plot shows higher NXNL2 RNA expression in normal versus tumor tissue (log2 FC = −2.334, t-test p < 0.001).
This table shows molecular features associated with NXNL2 in patient tissues and cancer cell lines. In patient samples, NXNL2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NXNL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
